MODERNA, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 117.3 USD | -4.38% |
|
-6.09% | +18.03% |
ETFs positioned on Moderna, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.66% | 0 M€ | 0.00% | - | |
| 4.69% | 2 M€ | -.--% | ||
| 4.08% | 0 M€ | 0.00% | - | |
| 2.50% | 0 M€ | -2.17% | - | |
| 2.40% | 0 M€ | +7.69% | - | |
| 2.08% | 7 M€ | -.--% | - | |
| 1.81% | 0 M€ | 0.00% | ||
| 1.36% | 9 M€ | -4.31% | - | |
| 1.21% | 1 M€ | +2.21% | - | |
| 0.90% | 0 M€ | +2.39% | ||
| 0.81% | 0 M€ | 0.00% | - | |
| 0.72% | 0 M€ | +8.89% | ||
| 0.63% | 0 M€ | 0.00% | - | |
| 0.60% | 9 M€ | -.--% | - | |
| 0.55% | 5 M€ | -72.95% | - | |
| 0.45% | 0 M€ | 0.00% | - | |
| 0.34% | 0 M€ | -.--% | ||
| 0.30% | 0 M€ | +14.93% | ||
| 0.22% | 0 M€ | +18.09% | - | |
| 0.21% | 0 M€ | +5.47% | - | |
| 0.21% | 0 M€ | +1.36% | - | |
| 0.21% | 0 M€ | +5.47% | - |
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
122.7
USD
Average target price
139.4
USD
Spread / Average Target
+13.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.03% | 47.02B | |
| +48.77% | 41.86B | |
| +0.84% | 41.76B | |
| -4.27% | 28.8B | |
| +11.90% | 26.05B | |
| -21.50% | 19.15B | |
| +4.24% | 12.55B | |
| +28.43% | 12.34B | |
| -4.33% | 11.82B | |
| +20.33% | 11.8B |
- Stock Market
- Equities
- MRNA Stock
- Funds and ETFs Moderna, Inc.
